Kymriah: England Becomes First In Europe To Say Yes To CAR-T
A new deal between Novartis and England’s National Health Service is one of the fastest funding approvals in the 70-year history of the NHS.
You may also be interested in...
Gilead suggests that the UK could take lessons from France on rapidly making innovative new treatments available after approval.
Novartis has managed to temporarily overcome payer reservations about the real-world value of Kymriah by engaging early with payers and heath technology assessment bodies and by developing tailored outcomes-based deals for key European markets. Approaching each payer with a responsible attitude has helped too.
Sir Andrew Dillon is leaving his role as CEO of England’s health technology assessment body after 20 years.